Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - Edgewise Therapeutics, Inc. | ewt-20210331xex31d2.htm |
| EX-31.1 - EX-31.1 - Edgewise Therapeutics, Inc. | ewt-20210331xex31d1.htm |
| EX-10.1 - EX-10.1 - Edgewise Therapeutics, Inc. | ewt-20210331xex10d1.htm |
| 10-Q - 10-Q - Edgewise Therapeutics, Inc. | ewt-20210331x10q.htm |
Exhibit 32.1
CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, Kevin Koch, certify, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, (1) the Quarterly Report on Form 10-Q of Edgewise Therapeutics, Inc. for the quarterly period ended March 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934and (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| | /s/ Kevin Koch |
| | Kevin Koch |
| | Chief Executive Officer and Director (Principal Executive Officer) |
| | Date: May 13, 2021 |
| | |
I, R. Michael Carruthers, certify, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, (1) the Quarterly Report on Form 10-Q of Edgewise Therapeutics, Inc. for the quarterly period ended March 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934and (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ R. Michael Carruthers | ||
R. Michael Carruthers | ||
Chief Financial Officer (Principal Financial and Accounting Officer) | ||
Date: May 13, 2021 |